ln-145
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2018 (NCT03645928)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04111510 | Phase 2 | Dec 1, 2019 | Yale University |
| NCT03645928 | Phase 2 | Oct 31, 2018 | Iovance |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Iovance | For profit | 1 | 1 | 1 | 2018 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1